Zynex, Inc. (ZYXI)
- Previous Close
11.45 - Open
11.42 - Bid 11.30 x 100
- Ask 11.38 x 100
- Day's Range
11.24 - 11.70 - 52 Week Range
6.88 - 14.75 - Volume
181,319 - Avg. Volume
217,391 - Market Cap (intraday)
363.36M - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
42.15 - EPS (TTM)
0.27 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 5, 2022
- 1y Target Est
19.88
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
www.zynex.com1,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ZYXI
Performance Overview: ZYXI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZYXI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZYXI
Valuation Measures
Market Cap
365.59M
Enterprise Value
397.18M
Trailing P/E
42.41
Forward P/E
22.88
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.25
Price/Book (mrq)
7.93
Enterprise Value/Revenue
2.15
Enterprise Value/EBITDA
22.20
Financial Highlights
Profitability and Income Statement
Profit Margin
5.28%
Return on Assets (ttm)
5.32%
Return on Equity (ttm)
17.30%
Revenue (ttm)
184.32M
Net Income Avi to Common (ttm)
9.73M
Diluted EPS (ttm)
0.27
Balance Sheet and Cash Flow
Total Cash (mrq)
44.58M
Total Debt/Equity (mrq)
165.12%
Levered Free Cash Flow (ttm)
19.11M
Research Analysis: ZYXI
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: ZYXI
ZYXI: Rating increased to a HOLD
ZYNEX INC has an Investment Rating of HOLD; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetZYXI: What does Argus have to say about ZYXI?
ZYNEX INC has an Investment Rating of SELL; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingBearishPrice TargetZYXI: What does Argus have to say about ZYXI?
ZYNEX INC has an Investment Rating of SELL; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingBearishPrice TargetZYXI: What does Argus have to say about ZYXI?
ZYNEX INC has an Investment Rating of SELL; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingBearishPrice Target